Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities: 2019-2020

Historic Other Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 2 years, with Nov 2020 value amounting to $850,000.

  • Nurix Therapeutics' Other Non-Current Liabilities fell 8.29% to $796,000 in Q3 2021 from the same period last year, while for Aug 2021 it was $796,000, marking a year-over-year decrease of 8.29%. This contributed to the annual value of $850,000 for FY2020, which is 51.07% down from last year.
  • According to the latest figures from FY2020, Nurix Therapeutics' Other Non-Current Liabilities is $850,000, which was down 51.07% from $1.7 million recorded in FY2019.
  • Over the past 5 years, Nurix Therapeutics' Other Non-Current Liabilities peaked at $1.7 million during FY2019, and registered a low of $850,000 during FY2020.
  • Its 2-year average for Other Non-Current Liabilities is $1.3 million, with a median of $1.3 million in 2019.
  • Data for Nurix Therapeutics' Other Non-Current Liabilities shows a maximum YoY slumped of 51.07% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows Nurix Therapeutics' Other Non-Current Liabilities stood at $1.7 million in 2019, then slumped by 51.07% to $850,000 in 2020.